Results 41 to 50 of about 3,081 (193)

Second primary cancers in lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia—cumulative burden without generalized excess cancer risk

British Journal of Haematology, EarlyView.
Summary Second primary cancers (SPCs) are a survivorship concern in lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia (LPL/WM), but estimates may be influenced by competing mortality and surveillance. We assessed cumulative incidence, relative risk and predictors of SPCs. We studied 521 patients diagnosed with LPL/WM in Region Zealand, Denmark,
Lars Munksgaard, Lars Moeller Pedersen, Lise Mette Rahbek Gjerdrum   +2 more
wiley   +1 more source

Cooperative miRNA-dependent PTEN regulation drives resistance to BTK inhibition in B-cell lymphoid malignancies

Cell Death and Disease, 2021
Aberrant microRNA (miR) expression plays an important role in pathogenesis of different types of cancers, including B-cell lymphoid malignancies and in the development of chemo-sensitivity or -resistance in chronic lymphocytic leukemia (CLL) as well as ...
Isha Kapoor, Juraj Bodo, Brian T. Hill, Alexandru Almasan   +3 more
doaj   +1 more source

Image_4_Real-world treatment patterns, discontinuation and clinical outcomes in patients with B-cell lymphoproliferative diseases treated with BTK inhibitors in China.pdf

, 2023
IntroductionBruton tyrosine kinase inhibitor (BTKi) has demonstrated substantial efficacy in treating B-cell lymphoproliferative diseases (BLPD). Nonetheless, the significant discontinuation rates due to toxicity or financial reasons cannot be overlooked.
Dehui Zou (9350856), Yuting Yan (2631160), Yuxi Li (3939713), Qi Wang (22418), Gang An (745176), Ying Yu (7066), Jianxiang Wang (179637), Rui Lv (3923345), Weiwei Sui (8678190), Wenjie Xiong (3836377), Shuhua Yi (3625865), Tingyu Wang (2299786), Yanshan Huang (1961035), Wenyang Huang (5774408), Lugui Qiu (187058)   +14 more
core   +1 more source

Expanded CD16+CD56+Granzyme B+ NK like CD8+ T cells an off target effect of bruton’s tyrosine kinase inhibitors in Waldenström macroglobulinemia

Scientific Reports
Bruton’s tyrosine kinase inhibitors (BTKi), widely used in Waldenström macroglobulinemia (WM), are known to impair B cell function, but their broader immunological effects remain unclear.
Priyanka Hastak, Chansavath Phetsouphanh, Zong-Hong Zhang, Rowena A. Bull, Lok Bahadur Shrestha, Vera Klemm, Raymond Louie, Fabio Luciani, C. Mee Ling Munier, Alexandra Carey Hoppé, Elizabeth Keoshkerian, Brendan Beaton, Katherine Rankin, Alexander Wong, Judith Trotman, Anthony D. Kelleher, Sarah C. Sasson   +16 more
doaj   +1 more source

SAKK 35/14 randomized trial of rituximab with or without ibrutinib for patients with untreated follicular lymphoma

British Journal of Haematology, EarlyView.
Summary The randomized phase II SAKK 35/14 trial, conducted by the Swiss Group for Clinical Cancer Research (SAKK) and the Nordic Lymphoma Group (NLG), compared efficacy and safety of rituximab (375 mg/m2 intravenously for 4 weeks followed by maintenance every 2 months for 24 months) plus placebo (arm A) versus the same schedule of rituximab plus ...
Maria Cristina Pirosa, Marianne Brodtkorb, Sämi Schär, Björn E. Wahlin, Micaela Hernberg, Michael Pedersen, Anastasios Stathis, Thilo Zander, Urban Novak, Thorsten Zenz, Natalie Fischer, Fatime Krasniqi, Felicitas Hitz, Ann‐Sofie Johansson, David Löfgren, Peter Albert Meyer, Anne Turid Bjørnevik, Giulio Sartori, Stefanie Hayoz, Andrea Fuhrer, Luzia Steiner, Francesco Bertoni, Luca Ceriani, Stefan Dirnhofer, Emanuele Zucca, Bjørn Østenstad   +25 more
wiley   +1 more source

Image_2_Real-world treatment patterns, discontinuation and clinical outcomes in patients with B-cell lymphoproliferative diseases treated with BTK inhibitors in China.pdf

, 2023
IntroductionBruton tyrosine kinase inhibitor (BTKi) has demonstrated substantial efficacy in treating B-cell lymphoproliferative diseases (BLPD). Nonetheless, the significant discontinuation rates due to toxicity or financial reasons cannot be overlooked.
Dehui Zou (9350856), Yuting Yan (2631160), Yuxi Li (3939713), Qi Wang (22418), Gang An (745176), Ying Yu (7066), Jianxiang Wang (179637), Rui Lv (3923345), Weiwei Sui (8678190), Wenjie Xiong (3836377), Shuhua Yi (3625865), Tingyu Wang (2299786), Yanshan Huang (1961035), Wenyang Huang (5774408), Lugui Qiu (187058)   +14 more
core   +1 more source

Venetoclax based regimens in octogenarian CLL patients: efficacy, safety and comparison to BTKi in a multicenter cohort [PDF]

: Octogenarians represent a significant fraction of patients with Chronic Lymphocytic Leukemia (CLL) but, despite the prevalence of the disease in this age group, limited data is available on the safety and efficacy of novel drugs in this subgroup.
Cellini, Alessandro, Ballotta, Laura, Lovato, Ester, Pasquale, Raffaella, Visentin, Andrea, Frustaci, Anna Maria, Moratti, Massimo, Innao, Vanessa, Patti, Caterina, Laurenti, Luca, Ferrarini, Isacco, Bullo, Martina, Moia, Riccardo, Noto, Alessandro, Trentin, Livio, Vitale, Candida, Martino, Enrica Antonia, Gentile, Massimo, Mazzetto, Federica, Cibien, Francesca, Innocenti, Idanna, Scarfò, Lydia, Sanna, Alessandro, Serafin, Andrea, Mauro, Francesca Romana, Derenzini, Enrico, Fresa, Alberto, Favrin, Gianmarco, Santambrogio, Elisa, Foglietta, Myriam, Varettoni, Marzia, Riemma, Costantino, Sportoletti, Paolo, Cuneo, Antonio, Marasca, Roberto, Orsucci, Lorella, Marchetti, Monia, Lista, Enrico, Coscia, Marta, Angotzi, Francesco, Tedeschi, Alessandra, Andriola, Costanza, Ghia, Paolo   +42 more
core   +2 more sources

Brexucabtagene autoleucel in-vivo expansion and BTKi refractoriness have a negative influence on progression-free survival in mantle cell lymphoma: Results from CART-SIE study [PDF]

Brexucabtagene autoleucel (brexu-cel) has revolutionized the treatment of patients affected by mantle cell lymphomas. In this prospective, observational multicentre study, we evaluated 106 patients, with longitudinal brexu-cel kinetics in peripheral ...
Ljevar, Silva, Angelillo, Piera, Stella, Federico, Chiappella, Annalisa, Cutini, Ilaria, Pennisi, Martina, De Philippis, Chiara, Zinzani, Pierluigi, Musso, Maurizio, Zinzani, Pier Luigi, Sorà, Federica, Krampera, Mauro, Massaia, Massimo, Martino, Massimo, Grillo, Giovanni, Magni, Martina, Bonifazi, Francesca, Bramanti, Stefania, Carniti, Cristiana, Farina, Mirko, Corradini, Paolo, Tisi, Maria Chiara, Arcaini, Luca, Barbui, Anna Maria, Patriarca, Francesca, Botto, Barbara   +25 more
core   +2 more sources

Heart failure medication to prevent cancer therapy–related cardiac dysfunction: A narrative review

British Journal of Pharmacology, EarlyView.
Advances in oncological therapies have improved cancer survival but also have increased the clinical incidence of cancer therapy–related cardiac dysfunction (CTRCD), a spectrum of conditions ranging from subclinical biomarker or strain abnormalities to progressive heart failure and cardiogenic shock.
Fabian Voß, Paul Goerke, Malte Kelm, Amin Polzin   +3 more
wiley   +1 more source

The role of Bruton's kinase inhibitors (BTKi) in accelerated Chronic Lymphocytic Leukemia (a-CLL): a case of successful response to acalabrutinib

, 2023
Objectives: The use of Bruton's tyrosine kinase (BTK) inhibitors has changed the clinical history of patients with chronic lymphocytic leukemia (CLL) in both naïve and relapsed/refractory settings. "Accelerated" chronic lymphocytic leukemia (a-CLL) is a
Zanni, Manuela, Paolo Rivela, Borra, Tiziana, Zacchi, Giulia, Tavarozzi, Rita, Giacomo Maria Pini, Giulia Zacchi, Federico Monaco, Tiziana Borra, Francesco Zallio, Lettieri, Maddalena, Carolina Gandolfo, Monaco, Federico, Daniela Pietrasanta, Ladetto, Marco, Rivela, Paolo, Pietrasanta, Daniela, Maddalena Lettieri, Pini, Giacomo Maria, Catania, Gioacchino, Manuela Zanni, Zallio, Francesco, Gioacchino Catania, Marco Ladetto, Rita Tavarozzi, Gandolfo, Carolina   +25 more
core   +1 more source